Peptide record

TPDB09885

Antibacterial Anticancer Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09885
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, and CancerPPD 2.0, with an available 3D structural model.
Sequence
SRSSRAGLQFPVGRIHRLLRK
Physicochemical Analysis
C106H184N40O26
NDCEMTWY
R
2434.88
13.00
7
0
7
+6
4.22
-0.629
92.86
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
4
Residue Composition
number
1
A
5
R
0
N
0
D
0
C
0
E
1
Q
2
G
1
H
1
I
3
L
1
K
0
M
1
F
1
P
3
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 5 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 2 H: 1 I: 1 L: 3 K: 1 M: 0 F: 1 P: 1 S: 3 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
21
C106H184N40O26
2434.88
13.00
+6
4.22
-0.629
Evidence Records 9 records
Evidence 1 Activity

Activity

MIC
Antibacterial
50 µM

Target

Staphylococcus aureus MTCC 3061

Source & Reference

NA

Other

Active against Gram+ B. cereus MCCB 101 (78% inhibition at 50 uM), S. aureus MTCC 3061 (MIC 50 uM), Gram- bacteria A. hydrophila MCCB 113 (68% inhibition at 50 uM), E. coli MTCC 483 (79% i
Evidence 2 Activity

Activity

MIC
Antibacterial
25 µM

Target

Pseudomonas aeruginosa MCCB 119

Source & Reference

NA

Other

E. coli MTCC 483 (79% inhibition at 50 uM), E. tarda MTCC 2400 (82% inhibition at 50 uM), P. aeruginosa MCCB 119 (MIC 25 uM), V. vulnificus WV13 (MIC 25 uM), V. fluvialis (85% inhibition at 50 uM), V. alginolyticus
Evidence 3 Activity

Activity

MIC
Antibacterial
25 µM

Target

V. vulnificus WV13

Source & Reference

NA

Other

50 uM), E. tarda MTCC 2400 (82% inhibition at 50 uM), P. aeruginosa MCCB 119 (MIC 25 uM), V. vulnificus WV13 (MIC 25 uM), V. fluvialis (85% inhibition at 50 uM), V. alginolyticus MTCC 4439 (89% inhibition at 50
Evidence 4 Activity

Activity

MIC
Antibacterial
50 µM

Target

V. cholerae MCCB 129

Source & Reference

NA

Other

luvialis (85% inhibition at 50 uM), V. alginolyticus MTCC 4439 (89% inhibition at 50 uM), V. cholerae MCCB 129 (MIC 50 uM), V-proteolyticus BCCM 3772 (MIC> 50 uM) and V. parahaemolyticus MTCC 451 (MIC 25 uM). Ant
Evidence 5 Activity

Activity

MIC
Antibacterial
25 µM

Target

V. parahaemolyticus MTCC 451

Source & Reference

NA

Other

n at 50 uM), V. cholerae MCCB 129 (MIC 50 uM), V-proteolyticus BCCM 3772 (MIC> 50 uM) and V. parahaemolyticus MTCC 451 (MIC 25 uM). Anticancer: XTT Cytotoxicity: HEp2 (TC50 31.2 uM) and NCI–H460 cancer cells (TC50 22.7 u
Evidence 6 Activity

Activity

0% Hemolysis
Toxicity
<100 µM
Hemolytic Cytotoxic
0% Hemolysis | <100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A histone H2A derived antimicrobial peptide, Fi-Histin from the Indian White shrimp, Fenneropenaeus indicus: Molecular and functional characterization. | Fish Shellfish Immunol | 2019
Evidence 7 Activity

Activity

5% Hemolysis
Toxicity
200 µM
Hemolytic Cytotoxic
5% Hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A histone H2A derived antimicrobial peptide, Fi-Histin from the Indian White shrimp, Fenneropenaeus indicus: Molecular and functional characterization. | Fish Shellfish Immunol | 2019
Evidence 8 Activity

Activity

18% Hemolysis
Toxicity
400 µM
Hemolytic Cytotoxic
18% Hemolysis | 400 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A histone H2A derived antimicrobial peptide, Fi-Histin from the Indian White shrimp, Fenneropenaeus indicus: Molecular and functional characterization. | Fish Shellfish Immunol | 2019
Evidence 9 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Fish Shellfish Immunol. 2019 Sep 92:667-679.